Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given
together with combination chemotherapy to compare how well they work in treating patients
with metastatic colorectal cancer.
RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.
Drugs used in chemotherapy, such as fluorouracil, leucovorin, oxaliplatin, and irinotecan,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving monoclonal antibodies together with combination
chemotherapy may kill more tumor cells. It is not yet known whether combination chemotherapy
is more effective with cetuximab and/or bevacizumab in treating patients with colorectal
cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Aptuit Inc. Bristol-Myers Squibb National Cancer Institute (NCI) Southwest Oncology Group